Lakefront Biotherapeutics (GLPGF) FCF Margin (2014 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported FCF Margin for 13 consecutive years, with 1274.91% the latest figure, recorded in Q1 2026.

• On a quarterly basis, FCF Margin fell 123021.0% year-over-year to 1274.91% in Q1 2026; TTM through Mar 2026 was 11.71%, a 1957.0% increase from a year earlier, with the FY2025 full-year figure at 21.92%, up 8812.0% from the prior year.
• FCF Margin was 1274.91% for Q1 2026 at Lakefront Biotherapeutics, down from 5.09% in the prior quarter.
• Over five years, FCF Margin peaked at 280.12% in Q4 2022 and troughed at 1274.91% in Q1 2026.
• A 5-year average of 126.42% and a median of 38.72% in 2022 frame the typical range for FCF Margin.
• Across the five-year window, FCF Margin soared 14542 bps in 2025 and tumbled 123021 bps in 2026, its largest moves.
• Over 5 years, FCF Margin stood at 280.12% in 2022, then slumped by 125 bps to 71.21% in 2023, then plunged by 102 bps to 143.86% in 2024, then jumped by 96 bps to 5.09% in 2025, then plunged by 24945 bps to 1274.91% in 2026.
• The last three FCF Margin figures came in at 1274.91% (Q1 2026), 5.09% (Q4 2025), and 4.01% (Q3 2025), per Business Quant data.